Information Provided By:
Fly News Breaks for January 2, 2019
Jan 2, 2019 | 08:43 EDT
Jefferies analyst Biren Amin initiated coverage of Synthorx (THOR) with a Buy rating and $21 price target. Based on preclinical data, the analyst believes THOR-707 could have differentiated properties compared to other IL-2 therapies and may drive monotherapy efficacy. He thinks THOR-707 will have a fast follower clinical development strategy to Nektar's (NKTR) NKTR-214. Further, Amin believes Synthorx's early pipeline offers additional upside.
News For THOR;NKTR From the Last 2 Days
There are no results for your query THOR;NKTR